VTv Therapeutics Inc.
VTVT
Rank in Stocks
#15746
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical... vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Share Price
$19.69
Last synced: 2026-11-13
Market Cap
$244.63M
Change (1 day)
-4.83%
Change (1 year)
-34.61%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade VTv Therapeutics Inc. (VTVT)
Category
Healthcare
Operating Margin for VTv Therapeutics Inc. (VTVT)
Operating Margin as of November 2026 TTM: -29.80%
According to VTv Therapeutics Inc.'s latest financial reports, its current operating margin (TTM) is -29.80%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for VTv Therapeutics Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -29.80% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -2,377.58% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -1,116.95% | 106.51% |
| 2021 | -540.87% | 192.71% |
| 2020 | -184.78% | -75.55% |
| 2019 | -755.86% | 374.10% |
| 2018 | -159.43% | -99.08% |
| 2017 | -17,416.49% | 100.69% |
| 2016 | -8,678.23% | 18.09% |
| 2015 | -7,349.13% | 293.94% |
| 2014 | -1,865.53% | -49.19% |
| 2013 | -3,671.41% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -195.39% | -93.44% |
US
|
|
| 33.87% | -101.14% |
US
|
|
| -116.04% | -96.11% |
US
|
|
| 25.57% | -100.86% |
AU
|
|
| 31.23% | -101.05% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about VTv Therapeutics Inc.'s operating margin
What is VTv Therapeutics Inc.'s operating margin?
VTv Therapeutics Inc.'s operating margin is -29.80%, as of Nov 2026.
What was VTv Therapeutics Inc.'s operating margin in 2025?
In 2025, VTv Therapeutics Inc.'s operating margin was 0.00%, compared with -2,377.58% in 2024.
How has VTv Therapeutics Inc.'s operating margin changed since 2020?
From 2020 to 2025, VTv Therapeutics Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-2,377.58%).
How does VTv Therapeutics Inc.'s operating margin compare with similar companies?
VTv Therapeutics Inc.'s operating margin (-29.80%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.